I am with aunt. Good results will mean accelerated approval submission. The stock will be up more than $3.
read it and your question will be answered......
unrelated third party investors
It was a 3rd party player. Not a principal.So Cognate raised debt with an offering and they used the proceeds for NWBO manufacturing business.
Also in the course of the review, the parties noted that Cognate had entered into two convertible debt financings with unrelated third party investors, secured by Cognate assets, and provided the proceeds of the financings for NWBO’s programs. The debt was convertible, at the investors’ election, into shares of Company stock owned by Cognate. The third party investors elected to convert the debt and receive repayment in shares of Company stock rather than in cash. In the review, the Company and Cognate noted that the debt conversions related to these two financings may be deemed to be “dispositions” of those Company shares for purposes of Section 16(b). Since the debt conversions by the third party investors were made within six months of the time that various issuances of Company stock were made by the Company to Cognate in payment of accounts
# 4 is probably the most important. It appears they are expecting catalysts to drive the shares higher. Must be thinking from the Direct trial. Also pick up on iHUB on this point.
That is a company that chopped around the $5 to $8 range for quite some time even when they had some revenues coming in. It took a while for people to notice it. $7 billion in market cap with $170 million in trailing sales. Cramer should have recommended it at $5.70. Here's your chance Jim!
She she pretty much believed they would become the standard of care for operable (with "L") and inoperable (with Direct) tumors having the same success they have been having. That is a remarkable view of things. The stock would be the market cap of AMGN over time.
Elevate Pharma another analysis house puts the revenue for "L" at $2 Billion by 2020. Much higher than GBI Research.
I think AA with Direct well before "L" is finished. Why buy such a big place? 12 Acres.
"On December 9, 2014, Aracaris Capital Ltd, a subsidiary of the Company in the UK, completed the purchase of the second portion of the property intended for the manufacturing expansion for DCVax products in the UK. This property is located within and surrounded by the first portion of the property already acquired by Aracaris, as previously reported. The purchase price for the additional property was �5 million (approximately $7.86 million). The additional property includes approximately 12 acres of potentially developable land (as well as non-developable land), and certain existing buildings. Development of the property for DCVax manufacturing will require approval by the Planning Commission to re-classify the property, removal of certain existing structures, making certain site improvements, Planning Commission approval of the intended use after re-classification, and Planning Commission approval of the specific designs and engineering. The Company plans to explore various structures and approaches for financing and/or development of the property that may enable the Company to withdraw its capital from the property."
I don't want a buyout but she should always say she is open to offers. When asked if she has had offers all she has to say is we don't comment on that subject. You may as well keep the shorts on their heels instead of being resolute.
The Q&A was decent at the end. The 55 patient off books "L" study is probably why German and UK authorities jumped to accelerate access. Direct results still good and now we know they will speed up the regiment in Phase II and inject multiple tumors. Perplexed at this share price so I will just need to keep accumulating. Nothing in that talk says to stop.
The trading activity has changed over the past 2 weeks. Less imbalance to the downside on my screen. Volume is up volume. Just my take looking at my quote server.
It would be nice if they put out the adjuvant testing data being done with DCVax - L. Nice discussion on iHUB. The results of the 9 patients with an RNA stimulant are stunning. Takes DCVax - L into a new stratosphere. No one will have these kind of results other than NWBO.
First of all you have no idea if Heights was able to get shares. All you have is AF's word on it. How good is that?
I would be shocked at that much but they will start to make money. More shocking is the 40,000 sq. ft. facility bought in the UK. They must be expecting sales in that region.
So Jerry how is your SEC investigation going? I bet they are jumping through hoops in Washington for you.